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Abstract
Carbapenems are usually regarded as the last treatment option for seri-
ous infections caused by Gram-negative and Gram-positive microorganisms. 
Although they are stable to hydrolysis by most β-lactamases, their usage as the last 
resort antbiotics was seriously compromised by the appearance of carbapenem-
hydrolyzing enzymes called carbapenemases. These enzymes are produced 
mostly by Enterobacteriaceae and Gram-negative nonfermentative bacteria such as 
Pseudomonas aeruginosa and Acinetobacter baumannii. True carbapenemases belong-
ing to Ambler molecular classes A, B, and D are often encoded by genes embedded 
in mobile genetic elements like plasmids, integrons, and transposons, which often 
harbor multiple resistance determinants limiting further the treatment options. At 
present, large number of nosocomial and community-acquired infections caused by 
worldwide spread of carbapenem-resistant Gram-negative bacteria have become a 
major public health problem. Although polymyxins remain active, in vitro reports 
of benefits of combination schemes favor this strategy against carbapenemase-
producing Gram-negative bacilli.
Keywords: carbapenems, carbapenemases, Enterobacteriaceae, Acinetobacter 
baumannii, Pseudomonas aeruginosa
1. Introduction
Carbapenems are bactericidal antibiotics often used as a last treatment option 
for severe infections caused by isolates producing extended-spectrum and/or AmpC 
β-lactamases. However, their stability to β-lactamases of Gram-negative bacteria is 
not absolute. From the first report of carbapenemases in the 1980s, the last decade is 
marked with the rapid spread of carbapenemases-producing organisms, becoming 
a public health concern worldwide.
2. Carbapenem antibiotics
Carbapenems are β-lactam antibiotics with broad antimicrobial spectrum, 
which encompasses Gram-positive and Gram-negative aerobic organisms and 
anaerobic bacteria. They often remain as the last treatment option for infections 
caused by multiresistant Gram-negative isolates. Their in vitro efficacy is due to 
good penetration through the outer membrane of Gram-negative bacteria, high 
affinity for penicillin-binding protein (PBP) molecules and excellent stability 
against β-lactamases [1]. The carbapenems bind to PBP-1 and PBP-2 and induce 
spheroplast formation and cell lysis without filament formation. They comprise 
imipenem, meropenem, ertapenem, and doripenem. In general, imipenem, and 
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doripenem are potent also against Gram-positive bacteria, while meropenem, 
ertapenem, and doripenem are slightly more effective against Gram-negative 
organisms. Ertapenem is not active against P. aeruginosa or A. baumannii, while 
doripenem has lower minimum inhibitory concentrations (MICs) than imipenem 
and meropenem versus P. aeruginosa and A. baumannii [1] Meropenem has an 
advantage over imipenem because it is not susceptible to renal dihydropeptidase 
and can be administered without cilastatin which is neurotoxic and contraindicated 
in neurological patients. Carbapenems are stable against wide range of serine-based 
β-lactamases including extended-spectrum β-lactamases (ESBLs), plasmid- 
mediated AmpC β-lactamases or against strains with inducible and derepressed 
expression of chromosomal AmpC β-lactamases. Although the stability against these 
common enzymes is not complete, the rate of hydrolysis is slow and only becomes 
significant when coupled with reduced outer membrane permeablity. Carbapenems 
are strong inducers of chromosomal β-lactamases, but β-lactamase induction does 
not affect their activity [2]. However, induction of chromosomal AmpC beta-lacta-
mase can cause antagonism with penicillins and cephalosporins, and thus carbapen-
ems should not be administed in combination with other β-lactams.
3.  Classification, historical background, and properties of 
carbapenemases
Some β-lactamases, named carbapenemases, can efficiently hydrolyze car-
bapenems [3]. These include chromosomal enyzmes, which are ubiquitious in 
some unusual pathogens and mostly environmental isolates (e.g., Stenotrophomonas 
maltophilia, Aeromonas spp., Flavobacterium spp., Bacteroides fragilis) and acquired 
carbapenemases of classes A, B, and D [3]. Although several class C carbapen-
emases have been described (ACT-1, CMY-2, CMY-10, and ADC-68), their produc-
ers usually exhibit reduced susceptibility to carbapenems as a consequence of low 
enzyme’s catalytic efficiency and a permeability defect. Therefore, they are not 
considered as true carbapenemases [4].
Based on the structure of their active site, carbapenemases are devided into 
two groups: class A-penicillinase and class D-oxacillinases; they contain serine at 
their active site and are inhibited by β-lactam inhibitors including clavulanic acid 
and tazobactam. The second group is metallo-β-lactamases belonging to class B 
which contain zinc atom at the active site and is inhibited by metal chelators such as 
ethylenediaminetetraacetic acid (EDTA) [5].
3.1 Class A carbapenemases
Serin carbapenemases of molecular (Ambler) group A are rare, detected 
mainly in Enterobacteriaceae. They belong to the functional subgroup 2f according 
to the classification scheme proposed by Bush et al. [6, 7]. The genes encoding 
them are located on either chromosome or plasmid. This group comprises SME-1 
(Serratia marcescens) [8], SME-2 (S. marcescens) [9], SME-3 (S. marcescens) [10], 
IMI-1 (Enterobacter cloacae) [11], NMC-A (E. cloacae) [12], KPC-1, KPC-2, and 
KPC-3 (Klebsiella pneumoniae) [13–15] and GES-2 (P. aeruginosa) [16]. They 
confer resistance to aminopenicillins, ureidopenicillins, first- and second-gener-
ation cephalosporins, aztreonam, and imipenem. Imipenem is hydrolyzed very 
slowly without causing a clinically relevant resistance [17]. SME β-lactamase was 
reported for the first time in S. marcescens in the UK in 1982 [8]. Infections caused 
by SME-positive S. marcescens are usually sporadic without potential of causing 
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outbreaks. IMI and NMC β-lactamases have been sporadically detected in isolates 
of E. cloacae in the USA, France, and Argentina [9, 10]. These β-lactamase are 
encoded chromosomally and have never been described on transferable genetic 
elements explaining their sporadic reports wordwide [17]. KPC-1 is a novel class 
A enzyme isolated in 1996 from K. pneumoniae in the USA [13]. The discovery of 
KPC-1 was quickly followed by two new allelic variants: KPC-2 and KPC-3 [14]. 
Subsequent revision of the blaKPC-1 sequence demonstrated that KPC-1 and KPC-2 
are identical enzymes [13–15]. KPC-3 differs from KPC-2 (the former KPC-1) by 
one amino acid change (H272Y) [14]. Although, so far, more than 20 different 
KPC variants have been described, KPC-2 and KPC-3 remain the most commonly 
identified. Unlike other class A carbapenemases, they hydrolyze expanded-spec-
trum cephalosporins and all carbapenems. KPC β-lactamases are weakly inhibited 
by clavulanic acid and tazobactam and are often coharbored with OXA-1 confer-
ring resistance to β-lactam inhibitor combinations. They are not inducible and are 
encoded on transferable plasmids. A 10-kb Tn3-type transposon Tn4401 with two 
insertion sequences ISKpn6 and ISKpn7 is repeatedly reported as the main genetic 
structure enhancing the spread of blaKPC-type genes [5]. Recently, a chromosal 
integration of the blaKPC gene was shown in K. pneumoniae, thus enabling easier 
maintenance of the gene in bacterial population [18]. Today, KPC enzymes are 
highly prevalent, not only found in K. pneumoniae but also in an increasing 
number of Enterobacteriaceae, P. aeruginosa, and A. baumannii. They are not only 
found all over the USA but also in Central and South America, while in European 
countries, KPC-producing isolates are mostly prevalent in Mediterranean coun-
tries, especially in Italy and Greece, countries reported as having endemic  
situation [19, 20].
They are also still present in Middle East where in 2007 a nationwide strategy 
was implemented to contain the outbreak faced by Israeli hospitals [21].
KPC-producing isolates are also reported in Asia, especially China where a hyper-
virulent Klebsiella pneumoniae strain K1-producing KPC is concerning [22, 23].
The main transporter in the worldwide dissemination of KPC-producing 
enzymes is succesfull clone Klebsiella pneumoniae ST258 [24]. In contrast to the 
majority of other class A carbapenemases, KPCs are typically plasmid mediated and 
usually carried on IncF plasmid. Plasmid location of blaKPC genes is responsible for 
the rapid dissemination of those important resistance determinants [23, 24].
GES-2 β-lactamase was derived by point mutation from GES-1 extended-
spectrum β-lactamase (with amino acid change G170 N) which was described in 
K. pneumoniae isolate from French Guinea [16, 25]. GES-2 β-lactamase was first 
reported from Pseudomonas aeruginosa from South Africa, was plasmid mediated, 
and conferred resistance or reduced susceptibility to carbapenems [26]. Because the 
enzymes have broad hydrolysis spectrum that includes penicillins and expanded-
spectrum cephalosporins, they were initially classified as ESBLs. Their hydrolysis 
spectrum was expanded in 2001 to include imipenem. GES β-lactamases are related 
to integron-borne-cephalosporinase—IBC) ESBLs, but confusing IBC names have 
been converted to GES [2, 3, 17]. Genes encoding GES family of β-lactamases are 
located on integrons embedded in plasmids with a possibility of conjugal transfer. 
However, they appear rarely in contrast to KPC β-lactamases and are not frequently 
associated with nosocomial outbreaks [3, 17, 26]. At present, the number of GES 
variants is increasing (with more then 20 described), but only several of them 
(mainly GES-2, -6, -14, -20) display carbapenemase activity (others are mostly 
ESBL). GES-type carbapenemases were identified in Pseudomonas aeruginosa, in 
Acinetobacter baumannii, and Enterobacteriaceae as well (mostly Klebsiella pneu-
moniae, Serratia marcescens, and Enterobacter spp. isolates) and have worldwide 
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distribution [17, 23]. In spite of the fact that they are plasmid mediated, they do not 
have a capacity for successful dissemination like KPC [23].
3.2 Class B carbapenemases
Metallo-β-lactamases (MBLs) are clinically the most relevant carbapenemases 
[23, 27]. This group of enzymes catalyzes the β-lactam hydrolysis by active site 
containing one or more bounded zinc ions that promote formation of nucleophilic 
hydoxide further attacking the β-lactam ring. The first descriptions of metallo-β-
lactamases included studies on environmental and opportunistic bacteria such as 
Stenotrophomonas maltophilia, Bacillus cereus, Aeromonas spp., Legionella gormanii, 
Pseudomonas stutzeri, Shewanella spp., Myroides odoratus, and so on, which carry 
MBLs on their chromosome but could present potential reservoir of mobile car-
bapenemase determinants [27, 28].
The metallo-β-lactamases or class B carbapenemases are further divided into 
subclasses (B1, B2 and B3), but the largest number of clinically relevant MBLs belong 
to B1 subclass, including the most frequently described Verona integron-encoded 
MBL (VIM), imipenemase (IMP), and New Delhi MBL (NDM). Those MBLs are 
usually located within different integron structures, and these integrons are associ-
ated with mobile plasmids or transposons facilitating the transfer of resistance genes 
between bacteria [3–5]. Acquired MBLs are reported from all over the world but 
mostly from Europe and Far East [27]. Transferable imipenem resistance was first 
detected in 1990 in Japan in P. aeruginosa isolate [29]. The β-lactamase-conferring 
imipenem resistance was designated IMP-1 and was located on a conjugative plasmid 
[30]. The same enzyme was later found on an integron in S. marcescens and other 
Enterobacteriaceae also in Japan. The first member of IMP family reported in Europe 
was IMP-1 found in A. baumannii in Italy [31]. The gene encoding this enzyme 
was located on class 1 integron [32]. Since that time, the IMP family was found 
throughout the world, but most reports originate from Far East [4, 22, 27, 33]. IMP-2 
β-lactamase was found in an Acinetobacter baumanni isolate from Italy in 1997 and 
shares 85% of amino acid identity with IMP-1 with similar kinetic parameters, while 
IMP-3 was reported in Shigella flexneri from Japan. That was the first appearance of 
MBL in typical community-acquired pathogen [34]. IMP-3 enzyme was previously 
known as MET-1, but the substrate specificity, that is, preferential hydrolysis of 
cephalosporins (and not penicilins and carbapenems), was a direct consequence of 
a single-base mutation (although the genes differ in two bases and two amino acid 
changes, that is, S262G and E126G). The gene and the enzyme were then renamed 
to blaIMP-3 or IMP-3 β-lactamase. Since IMP-1 shows broader substrate profile, it 
seemed that the gene blaIMP-3 was an ancestor of blaIMP-1 [27]. IMP-4 MBL was first 
reported from A. baumannii associated with nosocomial outbreak in Hong Kong in 
2001 [35]. IMP-5 was identified in urinary isolate of A. baumannii from Portugal 
in 2002, highly resistant to penicillins, broad-spectrum cephalosporins, including 
ceftazidime, ceftriaxone, cefepime, cefpirome, and to aztreonam, but remained 
susceptible to ampicillin/sulbactam, aminoglycosides, and quinolones [36]. IMP-5 
showed greater homology with IMP-1, IMP-3, and IMP-4 than with IMP-2. BlaIMP-5 
was the only gene cassette inserted into a class 1 integron, named In76. This was the 
first IMP-β-lactamase in Portugal and the second in Europe [36]. There are more 
than 50 allelic IMP variants reported so far [37]. They are usually devided into 
IMP-1 and IMP-2 cluster, suggesting their different phylogenetic origin. IMP-12, 
a very different variant outside the IMP-1 cluster (it has 85% similarity to IMP-1), 
has a unique structural feature and shows reduced catalytic effieciency toward 
penicillins [38]. IMP-51 was recently identified in a P. aeruginosa clinical isolate in 
Vietnam and showed increased doripenem- and meropenem-hydrolyzing activities 
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[39]. IMP-type enzymes have been reported all over the world in Enterobacteriaceae, 
P. aeruginosa, and A. baumannii but still represent the dominant carbapenemases 
in Japan and in Southeast Asia [33, 38, 40]. Analysis of the genetic platform of 
blaIMP genes has shown that most of them are embedded as gene cassettes in class I 
integron, harboring also other resistance genes, such as aac (mediating resistance to 
aminoglycosides), blaOXA (different serine oxacillinases), resistance to antiseptics, or 
chloramphenicol [38, 40, 41].
Another prevalent family of integron-associated metallo-β-lactamases is com-
posed of VIM enzymes. VIM means Verona integron-encoded metallo-β-lactamase 
because the first enzyme in this family was reported in Pseudomonas aeruginosa 
isolate from Verona in 1997 [42]. BlaVIM-1 gene was located within class 1 integron 
repeatedly showing the important role in the dissemination of IMP and VIM genes 
not only in nonfermentative bacteria but also in Enterobacteriaceae [4]. VIM-2 was 
described in Pseudomonas aeruginosa from France that was isolated in 1996 and 
shared 90% similarity with VIM-1 [43]. VIM-3 was reported in P. aeruginosa isolates 
associated with nosocomial outbreak from Taiwan [44]. The enzyme was chromo-
somally encoded and differed in two amino acids from VIM-1, namely C178A and 
A443G. VIM-4 β-lactamases were identified in K. pneumoniae and Enterobacter 
cloacae isolates from Italy in a patient previously treated with carbapenems and 
has one amino acid change in comparison to VIM-1 (S228A), being more active 
against imipenem than VIM-1 [45]. There are more than 40 allelic variants of VIM 
enzymes reported so far, and they mainly belong to three sublineages—VIM-1-
like, VIM-2-like, and VIM-7-like enzymes, representing phylogenetically the most 
divergent variants [38, 46]. VIM-2-like enzymes have been associated mostly with P. 
aeruginosa, whereas VIM-1-like enzymes, in particular, VIM-4, have been frequently 
reported in strains of the Enterobacteriaceae [38, 40, 46]. It is interesting to men-
tion that if VIM-1 or VIM-4 enzymes are found in E. cloacae and K. pneumoniae, 
mostly of ST147 and 11, they are usually carried on incompatibility group N or A/C 
plasmids, whereas in E. coli, those genes are often associated to IncFI/II plasmids 
[38, 41]. VIM-7, a more divergent enzyme, with lower efficiency for cephalosporins, 
was for the first time reported in the USA in 2001, and it was the first MBL in North 
America [47, 48]. North America was spared from MBLs until early 2000s. VIM 
enzymes are today widely distributed in all continents and at present the most 
common MBL found all over the world. In Mediterranean countries, such as Italy 
and Greece, VIM-positive P. aeruginosa strains of clonal complex 235 and 111 have 
been involved in nosocomial outbreaks [38]. The activity of aztreonam, as the only 
β-lactam not hydrolyzed by MBLs, is strongly compromised by the copresence of 
ESBLs, plasmid-mediated AmpC, or other serine β-lactamase together with MBLs 
[49, 50]. BlaVIM genes are typically embedded in class 1 integrons, which can be 
incorporated in either plasmids or chromosome. Plasmids carrying blaVIM genes in 
Enterobacterriaceae belong most frequently to IncA/C or IncN group [23, 38, 41].
NDM is a new family of metallo-β-lactamases unrelated to other MBLs. The first 
NDM-1 positive isolate from Europe was reported in Sweden from a patient who 
contracted a K. pneumoniae infection in India in late 2007 [51]. At the beginning, 
NDM enzymes spread in the Indian subcontinent, and they are still endemic in 
India, Pakistan, and Bangladesh. They were found not only in clinical isolates but 
also in public tap water and sewage water [52].
The spread soon involved the UK, historically related to India, but until now, it 
was described as present in all continents. However, it should be noted that Balkan 
region, Arabian Peninsula, and North African countries are considered as possible 
additional reservoirs of NDM-producing strains [38, 53, 54].
So far, the NDM enzymes have been found mostly in Enterobacteriaceae (with 
the importance of epidemic Klebsiella pneumoniae ST147, 11 and 14 and E. coli 
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ST131 and 405), P. aeruginosa, and A. baumannii. Enterobacteriaceae-producing 
NDM β-lactamases pose a serious public health concern because huge conjugative 
plasmids carrying the blaNDM genes can have up to 14 other antibiotic resistance 
determinants and can trasfer this resistance to other bacteria, resulting in multidrug 
resistance or pan-drug resistance phenotypes [55].
The genetic platform of blaNDM gene mostly involves transposon Tn125 with 
two flanking ISAba125 elements, often truncated in Enterobacteriaceae and part of 
broad-host-range plasmid including IncA/C (predominant plasmid type), F, R, 
H, N, L/M, and X types [38, 41, 53, 54]. NDM producers can acquire additional 
β-lactamases, even carbapenemases, and are recognized as the source of commu-
nity-acquired infections [54, 55]. The highest distribution of NDM variants (more 
than 15 so far) is detected in K. pneumoniae and E. coli species from Asian continent 
with China and India still serving as the major reservoir of NDM producers [38, 54].
A global surveillance study conducted through 2012–2014 enrolled 202 medical 
centers from 40 countries all over the world and identified 471 MBL-producing 
isolates of Pseudomonas aeruginosa and Enterobacteriaceae with 32 different MBL 
variants. Among them, seven novel allelic MBL variants were identified (VIM-42, 
-43, -44 and =45, IMP-48 and -49 and NDM-16), differing by one amino acid from 
previously reported enzymes proving still dynamic genetic background of these 
worldwide disseminated enzymes [56].
Other MBL-encoding genes are mostly limited to not only a single report or to 
particular geographic regions, including genes encoding SPM-1, GIM-1 and SIM-1, 
but also more recently described AIM-1, KHM-1, DIM-1, BIC-1, and TMB-1 [38, 
57–60]. GIM–MBL, unlike other class B carbapenemases, has two zinc ions in the 
active site.
SPM β-lactamases, originally described in P. aeruginosa strain from Brazil, are 
mostly limited to South America and have been associated with outbreaks at many 
hospitals. There were two imported cases in Europe until now, one in Switzerland, 
and one in the UK [57, 61, 62]. Unlike the other MBL-encoding genes, blaSPM gene 
was not part of gene cassette or integron, but it was located on plasmid and flanked 
with two expanded form is insertion segment common region (ISCR) elements 
probably providing its mobilization capacity [57]. The gene was also described in A. 
baumannii strain from Tehran [63].
3.3  Class D carbapenemases (carbapenem hydrolyzing class D β-lactamases; 
chdls)
The main characteristic of these enzymes is their hydrolytic activity toward 
oxacillin. Ambler group D carbapenemases include oxacillinases typical for 
Acinetobacter baumannii. [64]. OXA enzymes (the name came since they hydrolyze 
isoxazolylpenicillins much faster than penicillins) were recently divided into 12 
subgroups: OXA-23-like, OXA-24/40-like OXA-48, OXA-51-like, OXA-58-like, 
OXA-143-like, OXA-253, OXA-211, OXA-213, OXA-214, OXA-229, and OXA-235 
[65]. The amino acid sequence identities between members of the same subgroup 
are more than 90%, whereas the identities between enzymes that belong to dif-
ferent subgroups are less than 70% [65]. Enzymes belonging to OXA-51 group 
are naturally occurring β-lactamases of A. baumannii (often used as marker of 
identification) and are normally expressed at low levels but can be overexpressed 
as a consequence of the ISAba1 location upstream of the genes [64]. The clinically 
significant resistance is usually expressed in combination with other mechanisms 
like porin loss or upregulated efflux pumps. OXA-23 subgroup has been reported 
worldwide but most reports are coming from Acinetobacter baumannii isolates from 
Latin America. OXA-23-encoding gene is usually located on transposon Tn2006, 
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almost always bracketed on both sides by ISAba1 insertion sequence [5, 65–67]. It 
could be located on transferable plasmids, but it was also described integrated in 
the A. baumannii chromosome. OXA-24/40 subgroup was reported less frequently 
from A. baumannii, mostly from Iberian Peninsula and the USA [68]. It confers high 
level of carbapenem resistance and is usually chromosomally encoded. OXA-58 
and OXA-143 are usually plasmid mediated, first reported in France and Germany, 
respectively [69, 70]. Similar to OXA-23, blaOXA-58 is located within transposon 
usually bracketed by two copies of ISAba3. OXA-72 is the most prevalent allelic 
variant found in Europe, Far East, and South America [65, 71–73]. OXA-72 and 
OXA-23 variants have not only been identified in long-term care facilities but also in 
environmental samples such as municipal wastewater stressing the fact that strains 
resistant to antimicrobials are constantly circulating between the hospitals, com-
munity, and the nature [74–76].
Newer oxacillinase subgroups were mostly described as naturally occurring 
enzymes with low carbapenemase activity in Acinetobacter “non-baumannii“ iso-
lates like OXA-134a and OXA-143 in A. lwoffi, OXA-211 in A. johansonii, OXA-213 in 
A. calcoaceticus, OXA-214 in A. haemolyticus, OXA-229 in Acinetobacter bereziniae, 
and OXA-235 in Acinetobacter schindleri [65, 66, 70]. However, it is suggested that 
those enzymes present a reservoir of enzyme variants that could evolve to a more 
significant level and could be easily transferred to other bacterial species.
OXA-48 β-lactamase was originally described in a Klebsiella pneumoniae isolate 
from Istanbul, Turkey, in 2001 [77]. It is now widespread not only in Klebsiella 
pneumoniae but also in other Enterobacteriacea. Turkey was reported as having the 
highest epidemiologic level called endemic in 2015. The most important reservoirs 
of OXA-48 carbapenemases are linked with Turkey, India, Middle East, and North 
African countries [78]. blaOXA-48 gene is usually located in pOXA-48a plasmid, 
which belongs to the group of IncL/M plasmids. This plasmid has high conjugation 
rate, and it is self-conjugative, explaining partly the global dissemination of OXA-
48 enzymes [53]. The spread of blaOXA-48 gene is further mediated by IS1999 inser-
tion sequence located upstream of the Tn1999 transposon which is usually carried 
on L/M plasmid. In the majority of European countries, at present, it is the most 
prevalent type of carbapenemase among Enterobacteriaceae [65, 78].
OXA-48 hydrolyzes carbapenems at a low level, shows very weak activity 
against expanded-spectrum cephalosporins, and does not significantly hydrolyze 
ceftazidime and cefepime but in combination with impermeability can lead to 
high-level resistance to carbapenems [79]. OXA-48 significantly hydrolyze only 
penicillins and narrow-spectrum cephalosporins and like other class D enyzmes 
is not inhibited by clavulanic acid, sulbactam, or tazobactam leading to elevated 
MICs of amoxycillin/clavulanate and piperacillin/tazobactam, as shown in Table 1. 
Resistance to expanded-spectrum cephalosporins occurs only in strains positive for 
addtional ESBL or AmpC. Some OXA-48 variants, including OXA-181 (differing by 
four amino acids from OXA-48) and OXA-162 (with one amino acid substitution 
T213A) were also found in Enterobacteriaceae [78]. OXA-162 variant is also able 
to hydrolyze ceftazidime, whereas OXA-48 is not. Interestingly, OXA-181 is often 
associated with other carbapenemase genes, and many reports from Indian subcon-
tinent describe isolates coproducing OXA-181, NDM-1, and VIM enzymes [80].
In a recent report, environmental species, Shewanella xiamenensis was identi-
fied as the progenitor of the blaOXA-181 gene [81]. It is therefore hypothesized that a 
mobilization of a chromosomal gene to plasmid happened, and then the gene dis-
seminated further in clinically relevant species. This work emphasizes the constant 
interplay between microorganisms in the environment, community, and clinics. 
Gram-negative bacteria are ubiquitous in nature and are widely distributed in soil 
and water where they can survive for a long time posing a possible reservoir of 
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Type of 
carbapenemase
Substrate profile Inhibiton 
by
Country of 
origin
Host 
species
Reference
Penicillins Narrow-
spectrum 
cephalosporins
Expanded-
spectrum 
cephalosporins
Aztreonam Imipenem Meropenem
Class A
IMI + + — — + — Clavulanic 
acid
France E. cloacae [11]
NMC + + — — + — Clavulanic 
acid
France E. cloacae [12]
SME-1 + + — — + — Clavulanic 
acid
United 
States
S. 
marcescens
[8]
SME-2 + + — — + — Clavulanic 
acid
United 
States
S. 
marcescens
[9]
SME-3 + + — — + — Clavulanic 
acid
United 
States
S. 
marcescens
[10]
KPC-1 + + + + + + PBA United 
States
K. 
pneumoniae
[13]
KPC-2 + + + + + + PBA United 
States
K. 
pneumoniae
[13, 15]
KPC-3 + + + + + + PBA United 
States
K. 
pneumoniae
[14]
GES-2 + + — — + — Clavulanic 
acid
French 
Guinea
P. 
aeruginosa
[16]
Class B
IMP-1 + + + — + + EDTA Japan P. 
aeruginosa
[29]
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Type of 
carbapenemase
Substrate profile Inhibiton 
by
Country of 
origin
Host 
species
Reference
Penicillins Narrow-
spectrum 
cephalosporins
Expanded-
spectrum 
cephalosporins
Aztreonam Imipenem Meropenem
IMP-2 + + + — + + EDTA Italy A. 
baumannii
[32]
IMP-4 + + + — + + EDTA Japan A. 
baumannii
[35]
IMP-5 + + + — + + EDTA Portugal A. 
baumannii
[36]
VIM-1 + + + — + + EDTA Italy P. 
aeruginosa
[42]
VIM-2 + + + — + + EDTA France P. 
aeruginosa
[43]
VIM-3 + + + — + + EDTA Taiwan P. 
aeruginosa
[44]
VIM-4 + + + — + + EDTA France E. cloacae, 
K. 
pneumoniae
[45]
VIM-7 + + — — + + EDTA USA P. 
aeruginosa
[47]
NDM-1 + + + — + + EDTA Sweden K. 
pneumoniae
[51]
GIM-1 + + + — + + EDTA Germany P. 
aeruginosa
[58]
SPM-1 + + + — + + EDTA Brasil P. 
aeruginosa
[57]
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Type of 
carbapenemase
Substrate profile Inhibiton 
by
Country of 
origin
Host 
species
Reference
Penicillins Narrow-
spectrum 
cephalosporins
Expanded-
spectrum 
cephalosporins
Aztreonam Imipenem Meropenem
SIM-1 + + + — + + EDTA South Korea P. 
aeruginosa
[59]
DIM-1 + + + — + + EDTA The 
Netherlands
P. 
aeruginosa
[60]
Class D
OXA-48-like + + — — + — Turkey K. 
pneumoniae
[77]
OXA-23 (ARI-1) + + + + + + UK A. 
baumannii
[67]
OXA-24/40-like + + + + + + NaCl Spain A. 
baumannii
[68]
OXA-58-like + + + + + + France A. 
baumannii
[69]
OXA-143-like + + + + + + Germany A. 
baumannii
[70]
OXA-253 + + + + + + Germany A. 
baumannii
[65]
The most prevalent allelic variants are shown. Abbreviations: PBA-phenylboronic acid; EDTA-ethylenediaminetetraacetic acid.
Table 1. 
Classification, substrate profile, susceptibility to inhibitors, host species, and county of origin of carbapenemases.
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resistance determinants. Main characteristics of the most prevalent allelic variants 
of the Ambler classes A, B, and D carbapenemases are shown in Table 1.
4. Clinical significance of carbapenemases
Carbapenemase-producing Gram-negative bacteria can cause a wide spectrum 
of infections including bacteremia, nosocomial pneumonia, wound infections, 
endocarditis, and urinary tract infections. Risk factors for carbapenem-resistant 
isolates usually include procedures involving manipulations of the gastrointestinal 
tract, trauma, orthopedic procedure, or life-threatening conditions like septicemia 
and septic shock. Those infections are often associated with high hospitalization 
cost, treatment failures, longer hospital stay, and high mortality rates [82–84].
5. Laboratory detection
Appropriate and timely laboratory detection of carbapenemase-producing 
microorganisms is of crucial importance to implement adequate antimicrobial 
therapy. Screening for carbapenemase production is usually based on reduced inhi-
bition zones around carbapenem disks in routine disk-diffusion testing or elevated 
MICs for carbapenems. However, the level of resistance depends on the type of 
carbapenemase, allelic variant, gene expression, and/or the presence of additional 
resistance mechanisms such as porin loss or upregulation of efflux pumps.
Recommendations for carbapenem susceptibility breakpoints have been 
established by both Clinical Laboratory Standards Institute (CLSI) and The 
European Committee on Antimicrobial Susceptibility Testing (EUCAST), but no 
global consensus exists with EUCAST breakpoints being generally lower [85, 86]. 
However, some strains with low-level resistance are still being missed. EUCAST has 
also established epidemiologic breakpoints to distiguish between wildtype isolates 
and those with carbapenem-resistant determinants [86].
Ideally, methods for identifying carbapenemase should have a short turnaround 
time to ensure timely implementation of control measures. This could be challenged by 
difficulties in detecting carbapenemase producers, since MICs to carbapenems could 
be elevated but within susceptible range or even low, as described in Enterobacteriaceae 
and A. baumannii. Particularly in OXA-48-producing organisms, the MICs of 
carbapenemas can be very low. The screening usually relies on the reduction of the 
inhibition zone around ertapenem disk [87, 88]. However, relevant methodology with 
specific laboratory test has not yet been standardized. Modified Hodge test is the only 
test recommended by CLSI for the phenotypic detection of carbapenemase producers 
but often lacking sensitivity and specificity. There are also several inhibitor-based tests 
using different inhibitors (EDTA and phenantroline as inhibitors of MBLs, phenylbo-
ronic acid as inhibitor of KPC) in combination with carbapenem (e.g., meropenem) 
or cephalosporin (e.g., ceftazidime) in different formats—disk-diffusion or broth 
dilution or E-test [88]. There is no specific inhibitor that could be used in detection of 
class D carbapenemases, but there are reports on using temocillin disk (or combined 
with avibactam) for this purpose [88]. Carba NP (derived from the names Nordmann-
Poirel) test is a simple biochemical test based on hydrolysis of imipenem detectable by 
a change of color of the indicator due to decrease of pH. It is applicable in most micro-
biological laboratories, although the reference standard in detection of carbapenemase 
production is spectrophotometric measurement of carbapenem hydrolysis in the 
presence or absence of inhibitor, but it is still reserved for reference laboratories [89]. 
Recently, a new method for the detection of carbapenemases was described [90].  
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The test was called carbapenem inactivation method (CIM), and it was based on 
degradation of meropenem by carbapenemase. The water suspension of carbapenem-
resistant microorganism is incubated with a 10-ug meropenem disk for 2 h. After incu-
bation, the disk is removed from the suspension and placed onto a Mueller-Hinton agar 
plate previously inoculated with the carbapenem-sensitive microorganism (usually 
Escherichia coli). If the carbapenem-resistant microorganism produces carbapenemase, 
consequently, meropenem will be hydrolyzed and the indicator (carbapenem suscep-
tible) microorganism will grow close to the disk [90]. CIM method has high sensitivity, 
comparable to that of Carba NP test, as reported recently [91]. Modified CIM test 
includes preparation of the bacterial suspension in tryptic soy broth and extending 
the time of incubation to 4 hours improving the detection of some carbapenemases in 
Enterobacteriaceae [92]. Recently, the use of mass spectrometry (matrix-assisted laser 
desorption/ionization-time of flight—MALDI-TOFF) based on analysis of degrada-
tion of carbapenem-molecule-enabled rapid detection of KPC carbapenemase (in 
45 min) or MBL (150 min) [93]. Finally, simplex or multiplex PCR, real-time PCR, or 
hybridization tests could significantly improve detection of carbapenemase genes in 
clinical laboratory bypassing the sensitivity and specificity problems with phenotypic 
tests [89]. However, molecular methods require expensive equipment and trained 
laboratory stuff.
6. Therapeutic options
Colistin is usually the last resort antibiotic for the treatment of infections associ-
ated with carbapenemase-producing Gram-negative bacteria. However, nephro-
toxicity and neurotoxicity are of clinical concern [94]. Colistin-resistant isolates of 
A. baumannii, P. aeruginosa, and K. pneumoniae have emerged recently leading to 
pan-drug resistant phenotypes with modified outer membrane lipopolysaccharide 
[95–97]. The optimal treatment approach for infection caused by carbapenemase-
producing Gram-negative bacilli remains a controversy. Still, a combination therapy 
is strongly recommended and includes two or more antibiotics active in vitro such 
as colistin, tigecycline, amikacin, aztreonam, or carbapenem in different combina-
tion schemes [98, 99]. Colistin is not recommended as monotherapy because of the 
development of heteroresistance. The combinations of colistin with rifampicin, 
vancomycin, and meropenem were shown to be synergistic in A. baumannii in vitro 
by chequerboard, 2-well and time-kill metod, but the results of the randomized, 
controlled clinical trials are controversial [99–101]. If the pathogen is suspected 
to be MBL producer, aztreonam may present the core drug (if the isolate does 
not possess other extended-spectrum or ampC β-lactamase), but if the patient is 
critically ill, the combination therapy with three drugs is preferred. If aminogly-
cosides or fosfomycin retain in vitro activity, for any serious infection, then they 
should not be using monotherapy. However, oral fosfomycin should not be used 
for the management of any infection outside the urinary tract, and in critically ill 
patients, combination therapy should be considered. Tigecycline is recommended 
for skin and soft-tissue infection with carbapenemase-producing A. baumannii 
and Enterobacteriaceae. If MICs to meropenem are low or moderately high (up to 
16 μg/ml), high-dose meropenem can be administered by prolonged infusion [99, 
100]. Dual carbapenem-based regimen for carbapenem-resistant Enterobacteriaceae 
usually includes high-dose meropenem or high-dose doripenem with ertapenem, 
and it is also most effective if the third drug is added [99]. In bloodstream and 
respiratory tract infections colistin could be added, while in gastrointestinal and 
biliary tract infections colistin and tigecycline should be included. Newer β-lactam-
β-lactamase inhibitor combinations such as ceftolozan/tazobactam seem promising 
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in treatment of carbapenem-resistant Pseudomonas aeruginosa infections [102]. 
However, it is not effective against MBL-producing organisms. Continued reports 
should be acknowledged in efforts of optimizing therapy for infections caused by 
carbapenem-resistant Gram-negative bacili. Furthermore, there is an urgent need 
to develop new antimicrobials. Although antibiotics still represent the mainstream 
direction for the treatment, the alternatives to them should be taken into account, 
including vaccines, bacteriocins, and probiotics. The revival of old antibiotics 
should be supported by expanding the knowledge of their pharmacokinetics and 
pharmacodynamics in order to avoid side effects and resistance developments.
7. Conclusions
In the last decade, an epidemic spread of carbapenamases among 
Enterobacteriaceae and Gram-negative nonfermentative bacilli was observed 
worldwide. The type of the most prevalent carbapenemase in a geographic region 
differs and might be associated with historical or cultural connections and exchange 
of people between countries where certain types of carbapenemase are endemic 
including the transfer of patients or staff across the borders, medical tourism, 
and migration of refugees. Particularly alarming is the fact that carbapenemases 
are not restricted only to hospital isolates any more. They have been reported and 
are continuously circulating between hospitals, long-term care facilities, com-
munity, and the environment. In conclusion, facing the global dissemination of 
carbapenemase-producing Gram-negative bacteria, and awaiting for the new 
antimicrobials to appear, a reasonable approach including hand hygiene, contact 
precautions, rational antibiotic usage, and active surveillance should be part of an 
intensive strategy aimed to reduce the incidence of colonization and infections with 
carbapenem-resistant microorganisms and to stop the spread of these bacteria into 
the community or the environment and vice versa.
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